


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

What is claimed is:

1. (Currently Amended) A compound of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof;



(1)

wherein

R^1 and R^2 are independently hydrogen, F, CF_3 , C_{1-3} alkyl, or R^1 and R^2 may together with the carbon atom to which they are attached form a 3 to 6-membered cycloalkyl ring;

R^4 and R^5 are independently hydrogen, C_{1-6} alkyl, perfluoro C_{1-6} alkyl, $-OC_{1-3}$ alkyl, perfluoro OC_{1-6} alkyl, halogen, or cyano;

R^7 and R^8 are independently H, F, CF_3 , or C_{1-3} alkyl, and the carbon to which R^7 and R^8 are bonded is attached to the benzene ring either meta or para to the depicted oxygen;

n is 1 or 2;

y is 1 or 2;

R^6 is phenyl or a 5- or 6-membered heteroaryl group, where the phenyl or heteroaryl group is optionally substituted with 1, 2, or 3 moieties selected from the group consisting of C_{1-6} alkyl, halogen, perfluoro C_{1-3} alkyl, OC_{1-3} alkyl, perfluoro OC_{1-3} alkyl, SC_{1-3} alkyl, SO_2C_{1-3} alkyl, SO_2C_{1-3} perfluoroalkyl, SOC_{1-3} perfluoroalkyl, SOC_{1-3} alkyl, perfluoro SC_{1-3} alkyl, CN, and phenyl [[()]] optionally substituted with one or two groups selected from halogen, C_{1-3} alkyl, OC_{1-3} alkyl, acetyl, CN, and perfluoro C_{1-3} alkyl $[[()]]$, and or

R^6 is phenyl or a 5- or 6-membered heteroaryl group, where the phenyl or heteroaryl group is optionally substituted with 1, 2, or 3, 5- or 6-membered heteroaryl

moieties ~~[[()]]~~ optionally substituted with one group selected from C₁₋₃alkyl, C₃₋₆cycloalkyl, perfluoroC₁₋₃alkyl, NHC₁₋₃alkyl, and N(C₁₋₃alkyl)₂~~[[()]]~~; and

R³ is a 5- or 6-membered heteroaryl group optionally substituted by 1 or 2 moieties selected from the group consisting of halogen, C₁₋₆alkyl, perfluoroC₁₋₆alkyl, OC₁₋₃alkyl, and phenyl ~~[[()]]~~ optionally substituted with one or two moieties selected from C₁₋₃alkyl, halogen, OC₁₋₃alkyl, acetyl, CN, O~~perfluoro~~C₁₋₃alkyl, and perfluoroC₁₋₃alkyl~~[[()]]~~, or

R³ is a 5- or 6-membered heteroaryl group optionally substituted by 1 or 2 moieties selected from the group consisting of

5- or 6-membered heteroaryl ~~[[()]]~~ optionally substituted with one or two moieties selected from C₁₋₃alkyl, halogen, OC₁₋₃alkyl, acetyl, CN, and perfluoroC₁₋₃alkyl~~[[()]]~~,

hydroxyC₁₋₃alkyl, C₃₋₇cycloalkyl, cyanoC₁₋₃alkyl, acetyl, nitro, N(CH₃)₂, NHR²¹ ~~(where R²¹ is C₁₋₃alkyl, -C(O)C₁₋₃alkyl, -C(O)OC₁₋₃alkyl, or SO₂CH₃),~~ piperidin-4-yl ~~[[()]]~~ substituted at nitrogen with a moiety selected from C₁₋₅alkyl, benzyl, acetyl, C(O)OC₁₋₅alkyl, C(O)Obenzyl, C(O)NH₂, C(O)NHC₁₋₃alkyl, and SO₂CH₃~~[[()]]~~,

4-(4-fluorophenyl)piperazin-1-ylmethyl, morpholin-4-ylmethyl, tetrahydrofuran-3-yl, or two adjacent carbon atoms in the heteroaryl could be substituted to form a benzene ring thus forming a fused bicycle and wherein the resulting benzene ring is optionally substituted with one or two moieties selected from C₁₋₃alkyl, halogen, and perfluoroC₁₋₃alkyl; and

R²¹ is C₁₋₃alkyl, -C(O)C₁₋₃alkyl, -C(O)OC₁₋₃alkyl, or SO₂CH₃.

2. (Currently Amended) A compound ~~of~~ according to Claim 1 wherein R¹ and R² are independently hydrogen or C₁₋₃alkyl.

3. (Previously Presented) A compound according to Claim 1 wherein R¹ and R² are both hydrogen or both methyl.

4. (Previously Presented) A compound according to Claim 2 wherein R⁴ and R⁵ are independently hydrogen, C₁₋₃alkyl, perfluoroC₁₋₃alkyl, -OC₁₋₃alkyl, perfluoroOC₁₋₃alkyl, halogen, or cyano.

5. (Previously Presented) A compound according to Claim 4 wherein at least one of R^4 and R^5 are hydrogen
6. (Previously Presented) A compound according to Claim 5 wherein one of R^4 and R^5 is hydrogen and the other is not.
7. (Original) A compound according to Claim 6 wherein the one of R^4 and R^5 that is not hydrogen is ortho to the depicted oxygen.
8. (Previously Presented) A compound according to Claim 5 wherein R^7 and R^8 are independently hydrogen or methyl.
9. (Previously Presented) A compound according to Claim 5 wherein R^7 and R^8 are both hydrogen or both methyl.
10. (Previously Presented) A compound according to Claim 9 wherein y is 1.
11. (Currently Amended) A compound according to Claim 10 wherein R^6 is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF_3 , OCF_3 , and 5-membered nitrogen-containing heteroaryl ☐ optionally substituted with one group selected from C_{1-3} alkyl, C_{3-6} cycloalkyl, perfluoro C_{1-3} alkyl, NHC_{1-3} alkyl, and $N(C_{1-3}alkyl)_2$ ☐.
12. (Currently Amended) A compound according to any Claim 11 wherein R^3 is selected from the group consisting of pyrimidine, pyridine, pyridazine, pyrazine, 1,2,4-oxadiazole, oxazole, and thiazole; and R^2 is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6} alkyl, perfluoro C_{1-6} alkyl, phenyl ☐ optionally substituted with one or two moieties selected from C_{1-3} alkyl, halogen, OC_{1-3} alkyl, acetyl, CN, and perfluoro C_{1-3} alkyl☐,
5- or 6-membered heteroaryl ☐ optionally substituted with one or two moieties selected from C_{1-3} alkyl, halogen, OC_{1-3} alkyl, acetyl, CN, and perfluoro C_{1-3} alkyl☐.

hydroxyC₁₋₃alkyl, and C₃₋₇cycloalkyl, or R³ may be substituted to form a fused bicycle selected from benzoxazole and benzothiazole.

13. (Currently Amended) A compound according to Claim 12 wherein R³ is a pyrimidine or a pyridine; and is optionally substituted by a moiety selected from the group consisting of halogen, C₁₋₆alkyl, perfluoroC₁₋₆alkyl, 5- or 6-membered heteroaryl, hydroxyC₁₋₃alkyl, C₃₋₇cycloalkyl, and phenyl ~~[[()]] optionally substituted with one or two moieties selected from C₁₋₃alkyl, halogen, OC₁₋₃alkyl, acetyl, CN, and perfluoroC₁₋₃alkyl[()],]] 5- or 6-membered heteroaryl, hydroxyC₁₋₃alkyl, C₃₋₇cycloalkyl.~~

14. (Currently Amended) A compound according to Claim 1 selected from the group consisting of:

2-(4-{2-[[2,4-Bis(trifluoromethyl)benzyl](5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)-2-methoxyphenoxy]-2-methylpropanoic acid;

2-[2-Cyano-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[3-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(4-chlorobenzyl)(5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-ethylpyrimidin-2-yl)[3-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(5-Ethylpyrimidin-2-yl)(4-fluorobenzyl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]acetic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]acetic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-propylphenoxy]acetic acid;

5-Ethyl-*N*-(2-[3-propyl-4-(2*H*-tetraazol-5-ylmethoxy)phenyl]ethyl)-*N*-(4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]acetic acid;

5-ethyl-*N*-(2-methyl-2-[4-(2*H*-tetraazol-5-ylmethoxy)phenyl]propyl)-*N*-(4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]acetic acid;

2-[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)-2-propylphenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)-2-propylphenoxy]acetic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-methylphenoxy]-2-methylpropanoic acid;

2-[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-(trifluoromethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)-2-methylphenoxy]acetic acid;

[4-(2-((5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)-2-fluorophenoxy]acetic acid;

[2-Chloro-4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]acetic acid;

2-[4-(2-((5-Ethylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Ethylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Isopropylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-((5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-Methyl-2-[4-(2-((5-(2,2,2-trifluoroethyl)pyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]propanoic acid;

2-[4-(2-((5-(Hydroxymethyl)pyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(3-((5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino)propyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-([4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid; and

2-[4-(2-([4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid;
or a and pharmaceutically acceptable salt salts, solvates, acid isostere isosteres,
and or hydrolyzable ester esters thereof.

15. (Currently Amended) A compound according to Claim 1 selected from the group consisting of: 2-[4-(2-((5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino)-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid[.]; 2-[4-(2-([4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino)ethyl)phenoxy]-2-methylpropanoic acid[.]; and

2-[4-(2-([4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl])[4-(trifluoromethyl)benzyl]amino)ethyl]phenoxy]-2-methylpropanoic acid[[.]]; or a and pharmaceutically acceptable salt salts, solvates, acid isostere isosteres, and or hydrolyzable ester esters thereof.

16. (Currently Amended) A compound of according to Claim 1 wherein R¹ and R² are both hydrogen or both methyl; at least one of R⁴ and R⁵ are hydrogen; R⁷ and R⁸ are both hydrogen or both methyl; y is 1; R⁶ is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF₃, OCF₃, 5-membered nitrogen-containing heteroaryl ~~[[()]]~~ optionally substituted with one group selected from C₁₋₃alkyl, C₃₋₆cycloalkyl, perfluoroC₁₋₃alkyl, NHC₁₋₃alkyl, and N(C₁₋₃alkyl)₂~~[[()]]~~; and R³ is a thiazole, a pyrimidine, or a pyridine and is optionally substituted by a moiety selected from the group consisting of halogen, C₁₋₆alkyl, perfluoroC₁₋₆alkyl, 5- or 6-membered heteroaryl, hydroxyC₁₋₃alkyl, C₃₋₇cycloalkyl, and phenyl ~~[[()]]~~ optionally substituted with one or two moieties selected from C₁₋₃alkyl, halogen, OC₁₋₃alkyl, acetyl, CN, and perfluoroC₁₋₃alkyl~~[[()]]~~ ~~5- or 6-membered heteroaryl, hydroxyC₁₋₃alkyl, and C₃₋₇cycloalkyl.~~

17. (Previously Presented) A compound according to Claim 1 wherein the compound is a hPPAR agonist.

Claims 18 - 20 (Cancelled).

21. (Previously Presented) A pharmaceutical composition comprising a compound according to Claim 1.

Claims 22 - 23 (Cancelled).